TG Therapeutics (TGTX) investor relations material

Business overview and financial outlook

• Briumvi has been on the market for nearly three years, with a revenue target of $585 million for the current year and expectations for significant growth next year.

• No formal guidance for next year yet, but internal expectations are for a much larger revenue figure.

• Consolidated dosing study has completed enrollment, with data expected in mid to early second half of next year.

• Subcutaneous (sub-Q) program is enrolling well, with completion expected in the first half of next year and data by year-end.

• Revenues are expected to continue ramping as new data and programs progress.

Market dynamics and share

• Approximately 50-55% of MS patients use CD20 therapies, with IV accounting for about 60% and sub-Q for 35-40% of this segment.

• Briumvi captures about one-third of new IV anti-CD20 patients, translating to a 20% share in the CD20 class and 10% among all MS new starts.

• Patient awareness was 35% at last check, with a goal to double this over the next one to two years, potentially driving market share to 40%.

• Direct-to-consumer (DTC) efforts are ongoing to increase awareness and share, with a current ratio of awareness to market share at about 3.5 to 1.

• Expansion of the sales force will be targeted and strategic, aiming to address underperforming centers rather than broad geographic splits.

Product development and pipeline

• Sub-Q Briumvi phase I PK data is expected in the second half of next year.

• The sub-Q formulation is highly concentrated, developed in-house, and has provisional patents that could extend protection to 2045.

• The new sub-Q formulation will be filed as a new BLA and is expected to have its own IRA clock.

• Sub-Q market share is currently 35-40% and could potentially rise, but future trends are uncertain.

• Azer-cel phase I is progressing slowly, with hopes for more rapid enrollment and data presentation in 2026.